DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER (Información remitida por la empresa firmante) Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%.
CRAYFISH BIDCO OY EXTENDS THE OFFER PERIOD UNDER THE VOLUNTARY RECOMMENDED CASH TENDER OFFER FOR ALL SHARES IN CAVERION
CRAYFISH BIDCO OY EXTENDS THE OFFER PERIOD UNDER THE VOLUNTARY RECOMMENDED CASH TENDER OFFER FOR ALL SHARES IN CAVERION
Crayfish BidCo Oy extends the offer period under the voluntary recommended cash tender offer for all shares in Caverion
Crayfish BidCo Oy extends the offer period under the voluntary recommended cash tender offer for all shares in Caverion
Askel Healthcare has appointed globally renowned orthopedic surgeons and sports medicine specialists to its new Clinical
Neste celebrates the opening of the Singapore expansion and establishes a sustainable aviation fuel (SAF) supply chain t
